Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial

Phase 2b study found that natalizumab did not improve outcomes vs placebo as the rate of the composite primary endpoint (modified Rankin Scale score ≤1 and Barthel Index score ≥95 at day 90) was lower (OR 0.60, 95% CI 0.39-0.93).

Source:

Neurology